Not Yet RecruitingPhase 2/3

Ultrasound Guided Erectror Spinae Block Versus Intracavitary During Medical Thoracoscopy

100 participantsStarted 2026-05-15

Plain-language summary

The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri-procedural (intraoperative and post-operative 12 hours) nalbuphine consumption (mg) during medical thoracoscopy. Secondary aims: Time to first rescue analgesia, postoperative VAS, haemodynamics, recovery time (Aldert \> 9), and adverse events

Who can participate

Age range25 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 100 patients belonging to American Society of Anesthesiologists (ASA) I-III scheduled for medical thoracoscopy under adequate sedation and analgesia. Exclusion Criteria: * Patients will be excluded if; history of allergy or contraindication to any of the studied drugs, BMI more than 35 kg/m2, chronic opioid use or abuse, patients for whom ESPB block is contraindicated (patient refusal, coagulation disorder, skin infection at the injection site), history of post-thoracotomy, chest wall deformity, severe uncontrolled comorbidity, intubated patients, or if the interventional physician wants general anaesthesia from the start

What they're measuring

The primary aim: is to compare the effect of US guided ESP block at two levels versus intracavitary blockade in medical thoracoscopy on total peri procedural nalbuphine (mg) consumption during medical thoracoscopy

Timeframe: intraoperative and post-operative 12 hours

Trial details

NCT IDNCT07572019

SponsorKafrelsheikh University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-15

Contact for this trial

Donia Hany Hany, MD

01014498540 doniahany1788@gmail.com

View on ClinicalTrials.gov More PLEURA DISEASE trials